Enigma Biomedical Group USA Signs License Agreement With AbbVie For Novel 4R Tau PET Imaging Biomarkers
Portfolio Pulse from Benzinga Newsdesk
Enigma Biomedical Group USA (EBG-USA) has entered into an exclusive license and option agreement with AbbVie to develop and potentially commercialize AbbVie's F18 PET imaging biomarkers for detecting 4R tau protein in neurodegenerative diseases. The biomarkers could advance understanding and treatment of diseases like PSP and CBD. EBG-USA will collaborate with partners to validate the biomarkers, with an option for an exclusive license if evaluations are positive.
January 18, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie has licensed its next-generation F18 PET imaging biomarkers to EBG-USA for development and potential commercialization, which could enhance its portfolio in neurodegenerative disease diagnostics.
The agreement with EBG-USA could lead to the development of a significant diagnostic tool for neurodegenerative diseases, potentially opening up a new revenue stream for AbbVie if the biomarkers are successfully commercialized. This news is likely to be viewed positively by investors, as it demonstrates AbbVie's commitment to innovation in a high-need medical area. However, the impact is moderate as the commercialization is not immediate and depends on the success of the evaluations.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80